Get the Stockscreener App
33.79
1.31%
-0.45
Pre-market:
34.95
1.16
+3.43%
Aligos Therapeutics Inc stock is traded at $33.79, with a volume of 157.30K.
It is down -1.31% in the last 24 hours and down -15.19% over the past month.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$34.24
Open:
$34.28
24h Volume:
157.30K
Relative Volume:
0.37
Market Cap:
$121.23M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-1.3914
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
+12.45%
1M Performance:
-15.19%
6M Performance:
+168.33%
1Y Performance:
+99.06%
1-Day Range:
$32.50
$34.28
1-Week Range:
$30.31
$34.34
52-Week Range:
$6.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
33.79 | 121.23M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded - Simply Wall St
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Genetic Technologies (NASDAQ:GENE) - Defense World
4Q24 Wrap: They all fall down - BioCentury
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update - MarketBeat
Here’s Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing - MSN
How Is The Market Feeling About Aligos Therapeutics? - Benzinga
Why These 24 Stocks Are Skyrocketing - Insider Monkey
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aligos Therapeutics (NASDAQ:ALGS) & Artiva Biotherapeutics (NASDAQ:ARTV) Head to Head Contrast - Defense World
ALGS stock soars to 52-week high, hits $44.5 amid robust gains - Investing.com Nigeria
(ALGS) Long Term Investment Analysis - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
Aligos Therapeutics stock soars to 52-week high of $42.99 By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock soars to 52-week high of $42.99 - Investing.com India
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week - Yahoo Finance
Charles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Charles Schwab Investment Management Inc. Sells 19,403 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World
Aligos Therapeutics stock soars to 52-week high of $35.47 - Investing.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Awards Key Talent Retention Stock Options Under 2024 Inducement Plan | ALGS Stock News - StockTitan
Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) - Seeking Alpha
How To Trade (ALGS) - Stock Traders Daily
Aligos stock hits 52-week high at $30.01 amid robust gains - Investing.com India
Baker BROS. Advisors LP Decreases Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat
Aligos Therapeutics Inc (ALGS) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 140.3% in November - MarketBeat
Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth? - Simply Wall St
Aligos Therapeutics to Present at Investor Conferences in December - The Manila Times
Aligos Therapeutics to Present at Two Major Healthcare Investor Conferences in December | ALGS Stock News - StockTitan
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Aligos Therapeutics files $400M mixed securities shelf - MSN
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - The Manila Times
Aligos Reports 100% HBV Suppression Success, Strong MASH Treatment Results in Clinical Trials | ALGS Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com
ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com
Compass Therapeutics Inc (CMPX) Quarterly 10-Q Report - Quartz
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Aligos Therapeutics Inc (ALGS) Quarterly 10-Q Report - Quartzy
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright - Defense World
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Yahoo Canada Finance
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):